Loading…

Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation

Abstract Background Radiation-induced secondary breast cancer (BC) may be a concern after radiation therapy (RT) for primary breast cancer (PBC), especially in young patients with germline (g)BRCA–associated BC who already have high contralateral BC (CBC) risk and potentially increased genetic susce...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 2023-11, Vol.115 (11), p.1318-1328
Main Authors: van Barele, Mark, Akdeniz, Delal, Heemskerk-Gerritsen, Bernadette A M, Andrieu, Nadine, Noguès, Catherine, van Asperen, Christi J, Wevers, Marijke, Ausems, Margreet G E M, de Bock, Geertruida H, Dommering, Charlotte J, Gómez-García, Encarnacion B, van Leeuwen, Flora E, Mooij, Thea M, Easton, Douglas F, Antoniou, Antonis C, Evans, D Gareth, Izatt, Louise, Tischkowitz, Marc, Frost, Debra, Brewer, Carole, Olah, Edit, Simard, Jacques, Singer, Christian F, Thomassen, Mads, Kast, Karin, Rhiem, Kerstin, Engel, Christoph, de la Hoya, Miguel, Foretová, Lenka, Jakubowska, Anna, Jager, Agnes, Sattler, Margriet G A, Schmidt, Marjanka K, Hooning, Maartje J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Radiation-induced secondary breast cancer (BC) may be a concern after radiation therapy (RT) for primary breast cancer (PBC), especially in young patients with germline (g)BRCA–associated BC who already have high contralateral BC (CBC) risk and potentially increased genetic susceptibility to radiation. We sought to investigate whether adjuvant RT for PBC increases the risk of CBC in patients with gBRCA1/2-associated BC. Methods The gBRCA1/2 pathogenic variant carriers diagnosed with PBC were selected from the prospective International BRCA1/2 Carrier Cohort Study. We used multivariable Cox proportional hazards models to investigate the association between RT (yes vs no) and CBC risk. We further stratified for BRCA status and age at PBC diagnosis (40 years). Statistical significance tests were 2-sided. Results Of 3602 eligible patients, 2297 (64%) received adjuvant RT. Median follow-up was 9.6 years. The RT group had more patients with stage III PBC than the non-RT group (15% vs 3%, P 
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/djad116